Perrigo Company plc (NYSE; TASE: PRGO), an Ireland-based global provider of Consumer Self-Care Products, announced on Tuesday that it has completed the sale of its Generic Rx Pharmaceuticals business to US-based healthcare investment company, Altaris Capital Partners LLC.

The deal is valued at USD1.55bn, with customary adjustments, completing Perrigo's transformation to a global consumer self-care company.

Perrigo CEO and president, Murray S Kessler, said, 'Closing this transaction was another important milestone for Perrigo's transformation. We are now a leading pure-play global consumer self-care company that has significant resources to invest and has a passionate and committed team that is dedicated to making our vision a reality – To make lives better by bringing quality affordable self-care products consumers trust, everywhere they are sold. I am more excited than ever about the company's future.'